NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

NewAmsterdam Pharma Company, a clinical-stage firm focused on cardiometabolic diseases, announced CEO Michael Davidson’s participation in the Cowen 43rd Annual Health Care Conference on March 7 and 8, 2023. Davidson will discuss cardiovascular therapies and present the company's innovations. NewAmsterdam is developing obicetrapib, an oral CETP inhibitor, aimed at reducing LDL-C levels in high-risk cardiovascular patients. Previous trials, including ROSE and ROSE2, showed significant LDL-C reductions with obicetrapib. The company recently completed a $328 million business combination with Frazier Lifesciences and secured licensing rights for obicetrapib in Europe.

NAARDEN, the Netherlands and MIAMI, March 01, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will present at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 2:50 p.m. ET. In addition, he will participate in a panel discussion, titled “Cardiovascular Therapies” on Tuesday, March 7, 2023 at 4:40 p.m. ET.

A live webcast of Wednesday’s presentation will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). In addition, topline results from NewAmsterdam’s ROSE2 trial evaluating the combination of 10 mg obicetrapib and 10 mg ezetimibe demonstrated a median reduction in LDL-C levels of 59% versus baseline in patients on high-intensity statin therapy (vs. a 6% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam recently completed a business combination with Frazier Lifesciences Acquisition Corporation (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners. Proceeds from this transaction were approximately $328 million, prior to deducting transaction expenses. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease. For more information, please visit: www.newamsterdampharma.com.

Media Contact

Spectrum Science on behalf of NewAmsterdam
Carmen Lopez
P: 1 773-306-6285
clopez@spectrumscience.com

Investor Contact

Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1 212-362-1200
hannah.deresiewicz@sternir.com

FAQ

What is NewAmsterdam Pharma's stock symbol?

NewAmsterdam Pharma is traded under the symbols NAMS and NAMSW.

When will NewAmsterdam Pharma's CEO present at the Cowen Conference?

Michael Davidson will present on March 8, 2023, at 2:50 p.m. ET.

What is the focus of NewAmsterdam Pharma's research?

NewAmsterdam Pharma focuses on developing oral therapies for cardiometabolic diseases.

What results did the ROSE Phase 2b trial show for obicetrapib?

The ROSE Phase 2b trial showed a median LDL-C reduction of 51% in patients on high-intensity statin therapy.

What was the outcome of the ROSE2 trial for obicetrapib?

The ROSE2 trial demonstrated a 59% median reduction in LDL-C levels with obicetrapib combined with ezetimibe.

What funding did NewAmsterdam Pharma secure from the recent business combination?

NewAmsterdam Pharma secured approximately $328 million from its business combination with Frazier Lifesciences.

What exclusivity agreement did NewAmsterdam Pharma enter regarding obicetrapib?

NewAmsterdam entered an exclusive licensing agreement with Menarini Group for obicetrapib commercialization in Europe.